185 related articles for article (PubMed ID: 2098302)
1. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
[TBL] [Abstract][Full Text] [Related]
2. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Palumbo A; Boccadoro M; Garino LA; Gallone G; Frieri R; Pileri A
Eur J Haematol; 1992 Aug; 49(2):93-7. PubMed ID: 1397246
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z; Krejcí M; Bacovský J; Hejlová N; Kuca B; Svojgrová M; Franková H; Gumulec J; Janca J; Veprek K; Januska B; Lehanka F; Rezek Z; Praskac P; Cahová S; Vránová M; Papajík T; Králová E; Novotná J; Scudla V; Koza V; Drbal J; Faber E; Mareschová I; Hájek R
Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
12. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
13. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Salmon SE; Beckord J; Pugh RP; Barlogie B; Crowley J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):33-6. PubMed ID: 1948127
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
[TBL] [Abstract][Full Text] [Related]
15. [New protocols for myeloma chemotherapy plus IFN alpha].
Kitani T
Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
[TBL] [Abstract][Full Text] [Related]
16. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Björkholm M
Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
[No Abstract] [Full Text] [Related]
17. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
18. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
[TBL] [Abstract][Full Text] [Related]
19. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Westin J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.
Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M
Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
